198 related articles for article (PubMed ID: 9271260)
1. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
Harding JA; Engbers CM; Newman MS; Goldstein NI; Zalipsky S
Biochim Biophys Acta; 1997 Jul; 1327(2):181-92. PubMed ID: 9271260
[TBL] [Abstract][Full Text] [Related]
2. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies.
Maruyama K; Takizawa T; Yuda T; Kennel SJ; Huang L; Iwatsuru M
Biochim Biophys Acta; 1995 Mar; 1234(1):74-80. PubMed ID: 7880861
[TBL] [Abstract][Full Text] [Related]
3. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
4. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
5. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
6. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
8. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
10. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status.
Phillips NC; Gagne L; Tsoukas C; Dahman J
J Immunol; 1994 Mar; 152(6):3168-74. PubMed ID: 7908302
[TBL] [Abstract][Full Text] [Related]
11. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
Huwyler J; Yang J; Pardridge WM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
[TBL] [Abstract][Full Text] [Related]
12. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo.
Maruyama K; Takahashi N; Tagawa T; Nagaike K; Iwatsuru M
FEBS Lett; 1997 Aug; 413(1):177-80. PubMed ID: 9287139
[TBL] [Abstract][Full Text] [Related]
13. [Study on preparation and biodistribution of PEG-immunoliposomes with active carboxylic terminals].
Zhang YF; Xie SS; Hou XP; Gao X; Zhang S; Chen ZS
Yao Xue Xue Bao; 2000 Nov; 35(11):854-9. PubMed ID: 11218866
[TBL] [Abstract][Full Text] [Related]
14. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.
Klibanov AL; Maruyama K; Beckerleg AM; Torchilin VP; Huang L
Biochim Biophys Acta; 1991 Feb; 1062(2):142-8. PubMed ID: 2004104
[TBL] [Abstract][Full Text] [Related]
15. PEG-immunoliposome.
Maruyama K
Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
[TBL] [Abstract][Full Text] [Related]
16. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
17. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity.
Pan X; Lee RJ
Int J Pharm; 2007 May; 336(2):276-83. PubMed ID: 17212981
[TBL] [Abstract][Full Text] [Related]
18. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.
Dos Santos N; Allen C; Doppen AM; Anantha M; Cox KA; Gallagher RC; Karlsson G; Edwards K; Kenner G; Samuels L; Webb MS; Bally MB
Biochim Biophys Acta; 2007 Jun; 1768(6):1367-77. PubMed ID: 17400180
[TBL] [Abstract][Full Text] [Related]
19. Lipid composition is important for highly efficient target binding and retention of immunoliposomes.
Maruyama K; Kennel SJ; Huang L
Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5744-8. PubMed ID: 2377612
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids.
Phillips NC; Dahman J
Immunol Lett; 1995 Mar; 45(3):149-52. PubMed ID: 7558165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
